HydroxyTyrosol / TGF-β Cancer Research Results

HT, HydroxyTyrosol: Click to Expand ⟱
Features:

Hydroxytyrosol (HT; 3,4-dihydroxyphenylethanol) = phenolic compound from extra-virgin olive oil (EVOO) and olives; also formed from oleuropein metabolism. Small, water-soluble catechol with high antioxidant capacity.
Primary mechanisms (conceptual rank):
1) Direct ROS scavenging + lipid peroxidation inhibition (membrane protection).
2) NRF2 activation → endogenous antioxidant enzymes (HO-1, NQO1, GCLC).
3) Anti-inflammatory modulation (↓ NF-κB, ↓ COX-2, ↓ iNOS).
4) Mitochondrial protection / biogenesis support (model-dependent; PGC-1α linkage reported).
5) Anti-proliferative / pro-apoptotic signaling in cancer (dose- and model-dependent).
PK / bioavailability: well absorbed; rapid phase II metabolism (glucuronide/sulfate conjugates); short plasma half-life; free aglycone concentrations modest vs many in-vitro studies.
In-vitro vs systemic exposure: many cell studies use ≥10–100 µM; typical dietary/EVOO intake yields lower transient plasma levels (conjugated forms predominate).
Clinical evidence status: strongest data in cardiometabolic/vascular endpoints; oncology evidence largely preclinical; neuroprotection mechanistically plausible with limited RCT data.

Hydroxytyrosol is mostly only available from olive oil and leaves, but is available as a common supplement.
Hydroxytyrosol & oleuropein show the most consistent direct anti-CSC activity in multiple models (breast, colon, prostate).
Hydroxytyrosol is potent against CSC phenotypes.

Mechanisms:
-Blocks EMT, reducing transition into CSC-like states
-Inhibits Notch signaling
-Reduces CD44+ / CD24– CSC markers
-Inhibits hypoxia-driven stemness (HIF-1α suppression)

Hydroxytyrosol is especially active in:
-Breast CSCs
-Melanoma CSC-like cells
-Gastric CSC models

Hydroxytyrosol (HT) — Cancer-Relevant Pathways

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS tone / lipid peroxidation ↓ (low–mod dose); ↑ (high concentration only) ↓ P→R Antioxidant; membrane protection Catechol scavenger; at higher concentrations may induce pro-oxidant stress in tumors (model-dependent).
2 NRF2 axis ↑ (context-dependent) ↑ R→G Endogenous antioxidant induction ↑ HO-1/NQO1; protective in normal tissues; could support tumor stress resistance (context-dependent).
3 NF-κB / COX-2 inflammation ↓ ↓ R→G Anti-inflammatory Reduces pro-tumor inflammatory signaling; consistent with Mediterranean diet data.
4 Mitochondrial function ↔ / ↓ proliferation (model-dependent) ↑ (protective) R→G Bioenergetic stabilization Reported support of mitochondrial integrity in normal cells; may impair cancer cell proliferation via metabolic stress.
5 Apoptosis (caspase activation) ↑ (high concentration only) ↔ / ↓ R→G Pro-apoptotic in select tumors Observed at supra-physiologic exposures in vitro.
6 Ferroptosis axis ↓ (anti-lipid-ROS bias) ↓ P→R Inhibits lipid oxidation Strong antioxidant property may counter ferroptotic strategies (context-dependent).
7 Clinical Translation Constraint — — — Exposure limitations Rapid metabolism; plasma free HT lower than many in-vitro doses; best considered dietary adjunct.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr

Hydroxytyrosol (HT) — Cancer Stemness / EMT Axis (Addendum)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 EMT (Epithelial–Mesenchymal Transition) ↓ (model-/dose-dependent) ↔ R→G Reduces EMT-associated transcription (e.g., Snail, Twist) Reported attenuation of mesenchymal phenotype; relevance strongest in breast and melanoma models; mostly in-vitro.
2 CSC markers (CD44+/CD24–) ↓ (model-dependent) ↔ G Reduces stemness-associated phenotype Observed reduction in CSC-like populations in breast cancer models; requires supra-physiologic exposure in many studies.
3 Notch signaling ↓ (model-dependent) ↔ R→G Stemness pathway inhibition Downregulation of Notch pathway components reported; central to CSC maintenance; not universally replicated across tumor types.
4 HIF-1α / hypoxia-driven stemness ↓ (preclinical) ↔ R→G Suppresses hypoxia adaptation Reduced HIF-1α signaling may attenuate hypoxia-induced CSC traits; data strongest in gastric and breast models.
5 Tumor-type specificity Breast, Melanoma, Gastric (preclinical) — — CSC-like cell sensitivity Evidence largely limited to cell-line and xenograft systems; translational dosing gap remains significant.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr


Hydroxytyrosol (HT) — Alzheimer’s Disease–Relevant Axes

Rank Pathway / Axis Cells (neurons/glia) TSF Primary Effect Notes / Interpretation
1 Lipid peroxidation / neuronal membrane protection ↓ P Neuroprotective antioxidant Protects against oxidative membrane injury; aligns with AD oxidative stress hypothesis.
2 NRF2 activation ↑ R→G Endogenous antioxidant upregulation Supports neuronal resilience under oxidative stress.
3 Neuroinflammation (NF-κB) ↓ R→G Microglial modulation Reduces pro-inflammatory cytokines in models.
4 Mitochondrial integrity ↑ R→G Bioenergetic stabilization Improves mitochondrial function in neuronal models; may reduce apoptotic susceptibility.
5 Aβ toxicity modulation ↓ (preclinical) G Reduces amyloid-induced oxidative injury Animal/cell evidence; limited direct human AD trials.
6 Clinical Translation Constraint — — Dietary-level evidence Human data strongest for Mediterranean diet patterns; isolated HT supplementation lacks large AD RCTs.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr
TGF-β, transforming growth factor-beta: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-CS TCGA
Type:
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses.
Anti-inflammatory cytokine.
In normal tissues, TGF-β plays an essential role in cell cycle regulation, immune function, and tissue remodeling.
- In early carcinogenesis, TGF-β typically acts as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis.

In advanced cancers, cells frequently become resistant to the growth-inhibitory effects of TGF-β.
- TGF-β then switches roles and promotes tumor progression by stimulating epithelial-to-mesenchymal transition (EMT), cell invasion, metastasis, and immune evasion.

Non-canonical (Smad-independent) pathways, such as MAPK, PI3K/Akt, and Rho signaling, also contribute to TGF-β-mediated responses.

Elevated levels of TGF-β have been detected in many advanced-stage cancers, including breast, lung, colorectal, pancreatic, and prostate cancers.
 - The switch from a tumor-suppressive to a tumor-promoting role is often associated with increased TGF-β production and activation in the tumor microenvironment.

High TGF-β expression or signaling activity is frequently correlated with aggressive disease features, resistance to therapy, increased metastasis, and poorer overall survival in many cancer types.
Scientific Papers found: Click to Expand⟱
4632- HT,    Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, SUM159
CSCs↓, TumCMig↓, TumCI↓, β-catenin/ZEB1↓, Wnt↓, p‑LRP6↓, LRP6↓, cycD1/CCND1↓, EMT↓, Slug↓, Zeb1↓, Snail↓, Vim↓, SMAD2↓, SMAD3↓, TGF-β↓,
4636- HT,    Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/ß-catenin and TGFß signaling
- in-vitro, BC, SUM159 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vitro, BC, BT549
Wnt↓, β-catenin/ZEB1↓, LRP6↓, cycD1/CCND1↓, EMT↓, Slug↓, Zeb1↓, Snail↓, Vim↓, TGF-β↓, CSCs↓, TumCMig↓, chemoP↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 2,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 2,   EMT↓, 2,   LRP6↓, 2,   p‑LRP6↓, 1,   Wnt↓, 2,  

Migration ⓘ

Slug↓, 2,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 2,   TGF-β↓, 2,   TumCI↓, 1,   TumCMig↓, 2,   Vim↓, 2,   Zeb1↓, 2,   β-catenin/ZEB1↓, 2,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TGF-β, transforming growth factor-beta
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:376  Target#:304  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page